MDGL
MadrigalFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Successful late‑stage readouts and smooth regulatory/commercial execution could re-rate the stock dramatically from the current anchor, driven by high-margin hepatic franchise and limited direct competition.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
Clinical readout misses endpoints or is inconclusive
Momentum
42
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.90 · Bull $7.25 · Bear $0.73
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-16 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $678.93
Why
Momentum42 · Δ7d -24.4
Value41 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
42
26% active weight
Current posture
7d trendSoftening
Δ7d
-24.4
Δ21d
+11.7
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 42.0 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$12.35B
Beta
-1.02
Shares Out
23.06M
P/E (TTM) · Derived
-41.7
P/S (TTM)
18.04
P/FCF (TTM) · Derived
-51.84
Rev YoY
+126.8%
EPS YoY
-1.9%
Gross Margin
+92.9%
Op Margin
-41.9%
Net Debt
-$641.02M
Current Ratio
3.50
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology